Related Experiment Videos
Chemotherapy waste reduction through shelf-life extension
S E Walker1, J Iazzetta, C De Angelis
1Sunnybrook Health Science Centre, Toronto, Ontario.
The Canadian Journal of Hospital Pharmacy
|February 1, 1994
Summary
Extending the shelf-life for chemotherapy drugs like doxorubicin, epirubicin, and mitoxantrone significantly reduces medication waste. This cost-saving strategy improves healthcare economics without impacting patient outcomes.
Area of Science:
- Oncology
- Pharmacoeconomics
- Healthcare Management
Background:
- Healthcare systems face pressure to minimize drug expenditures while maintaining patient outcomes.
- Chemotherapy drug wastage represents a significant financial burden.
Purpose of the Study:
- To evaluate the impact of extending the shelf-life of doxorubicin, epirubicin, and mitoxantrone on medication wastage.
- To assess the economic implications of reduced chemotherapy waste.
Main Methods:
- Prospective, non-randomized, unblinded chemotherapy wastage audits were conducted over four months.
- Data collected from 18 institutional sites in Ontario before and after shelf-life extension.
- Audits compared wastage rates for doxorubicin, epirubicin, and mitoxantrone.
Main Results:
- Sites extending shelf-lives for doxorubicin, epirubicin, and mitoxantrone saw significant waste reduction.
- Epirubicin waste reduced to <1%, doxorubicin to <15%, and mitoxantrone to <35% at participating sites.
- Waste was eliminated entirely for these drugs at several institutions.
Conclusions:
- Appropriate extension of chemotherapy medication shelf-lives effectively reduces drug waste.
- This strategy offers a simple method for reducing healthcare expenditures without compromising patient health outcomes.
- Shelf-life extension simplifies IV chemotherapy protocols and reduces associated complications.